ARGX vs. DOCS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ARGX and DOCS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ARGX’s market capitalization of 33.18 billion USD is substantially larger than DOCS’s 11.59 billion USD, indicating a significant difference in their market valuations.
DOCS carries a higher beta at 1.32, indicating it’s more sensitive to market moves, while ARGX (beta: 0.04) exhibits greater stability.
ARGX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, DOCS is a standard domestic listing.
| Symbol | ARGX | DOCS |
|---|---|---|
| Company Name | argenx SE | Doximity, Inc. |
| Country | NL | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Healthcare Information Services |
| CEO | Timothy Van Hauwermeiren EMBA, | Jeffrey A. Tangney |
| Price | 543.48 USD | 61.69 USD |
| Market Cap | 33.18 billion USD | 11.59 billion USD |
| Beta | 0.04 | 1.32 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 18, 2017 | June 24, 2021 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of ARGX and DOCS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ARGX
16.83%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, ARGX’s Return on Equity of 16.83% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
DOCS
22.38%
Medical - Healthcare Information Services Industry
- Max
- 25.87%
- Q3
- 8.12%
- Median
- 2.99%
- Q1
- -18.32%
- Min
- -48.18%
In the upper quartile for the Medical - Healthcare Information Services industry, DOCS’s Return on Equity of 22.38% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ARGX
-118.38%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ARGX has a negative Return on Invested Capital of -118.38%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
DOCS
17.37%
Medical - Healthcare Information Services Industry
- Max
- 26.81%
- Q3
- 8.81%
- Median
- 2.09%
- Q1
- -11.56%
- Min
- -32.60%
In the upper quartile for the Medical - Healthcare Information Services industry, DOCS’s Return on Invested Capital of 17.37% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ARGX
37.53%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 37.53% places ARGX in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
DOCS
39.13%
Medical - Healthcare Information Services Industry
- Max
- 39.13%
- Q3
- 9.34%
- Median
- 1.37%
- Q1
- -15.05%
- Min
- -39.66%
A Net Profit Margin of 39.13% places DOCS in the upper quartile for the Medical - Healthcare Information Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ARGX
-1.24%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ARGX has a negative Operating Profit Margin of -1.24%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
DOCS
39.94%
Medical - Healthcare Information Services Industry
- Max
- 39.94%
- Q3
- 11.27%
- Median
- 3.94%
- Q1
- -9.81%
- Min
- -29.30%
An Operating Profit Margin of 39.94% places DOCS in the upper quartile for the Medical - Healthcare Information Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ARGX | DOCS |
|---|---|---|
| Return on Equity (TTM) | 16.83% | 22.38% |
| Return on Assets (TTM) | 13.45% | 17.65% |
| Return on Invested Capital (TTM) | -118.38% | 17.37% |
| Net Profit Margin (TTM) | 37.53% | 39.13% |
| Operating Profit Margin (TTM) | -1.24% | 39.94% |
| Gross Profit Margin (TTM) | 46.33% | 90.20% |
Financial Strength
Current Ratio
ARGX
7.29
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ARGX’s Current Ratio of 7.29 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
DOCS
6.97
Medical - Healthcare Information Services Industry
- Max
- 5.37
- Q3
- 3.30
- Median
- 1.91
- Q1
- 1.37
- Min
- 0.54
DOCS’s Current Ratio of 6.97 is exceptionally high, placing it well outside the typical range for the Medical - Healthcare Information Services industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio
ARGX
0.01
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
Falling into the lower quartile for the Biotechnology industry, ARGX’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
DOCS
0.01
Medical - Healthcare Information Services Industry
- Max
- 1.14
- Q3
- 0.65
- Median
- 0.16
- Q1
- 0.04
- Min
- 0.00
Falling into the lower quartile for the Medical - Healthcare Information Services industry, DOCS’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio
ARGX
-20.85
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ARGX has a negative Interest Coverage Ratio of -20.85. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
DOCS
--
Medical - Healthcare Information Services Industry
- Max
- 12.12
- Q3
- 3.11
- Median
- 1.20
- Q1
- -12.03
- Min
- -25.76
Interest Coverage Ratio data for DOCS is currently unavailable.
Financial Strength at a Glance
| Symbol | ARGX | DOCS |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 6.97 |
| Quick Ratio (TTM) | 6.68 | 6.97 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 0.01 |
| Debt-to-Asset Ratio (TTM) | 0.01 | 0.01 |
| Net Debt-to-EBITDA Ratio (TTM) | -189.75 | -0.82 |
| Interest Coverage Ratio (TTM) | -20.85 | -- |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ARGX and DOCS. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
DOCS
0.00%
Medical - Healthcare Information Services Industry
- Max
- 7.19%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DOCS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
DOCS
0.00%
Medical - Healthcare Information Services Industry
- Max
- 130.89%
- Q3
- 2.61%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DOCS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ARGX | DOCS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ARGX
48.48
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ARGX’s P/E Ratio of 48.48 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
DOCS
52.06
Medical - Healthcare Information Services Industry
- Max
- 114.57
- Q3
- 67.12
- Median
- 45.42
- Q1
- 28.19
- Min
- 6.48
DOCS’s P/E Ratio of 52.06 is within the middle range for the Medical - Healthcare Information Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ARGX
1.27
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
A Forward PEG Ratio of 1.27 places ARGX in the upper quartile for the Biotechnology industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
DOCS
2.41
Medical - Healthcare Information Services Industry
- Max
- 6.35
- Q3
- 2.93
- Median
- 2.00
- Q1
- 0.55
- Min
- 0.03
DOCS’s Forward PEG Ratio of 2.41 is within the middle range of its peers in the Medical - Healthcare Information Services industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ARGX
15.66
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ARGX’s P/S Ratio of 15.66 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
DOCS
20.31
Medical - Healthcare Information Services Industry
- Max
- 10.90
- Q3
- 5.95
- Median
- 2.46
- Q1
- 1.42
- Min
- 0.36
With a P/S Ratio of 20.31, DOCS trades at a valuation that eclipses even the highest in the Medical - Healthcare Information Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio
ARGX
7.35
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
DOCS
10.73
Medical - Healthcare Information Services Industry
- Max
- 12.91
- Q3
- 6.69
- Median
- 2.84
- Q1
- 1.88
- Min
- 1.03
The P/B Ratio is often not a primary valuation metric for the Medical - Healthcare Information Services industry.
Valuation at a Glance
| Symbol | ARGX | DOCS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 48.48 | 52.06 |
| Forward PEG Ratio (TTM) | 1.27 | 2.41 |
| Price-to-Sales Ratio (P/S, TTM) | 15.66 | 20.31 |
| Price-to-Book Ratio (P/B, TTM) | 7.35 | 10.73 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -432.72 | 43.20 |
| EV-to-EBITDA (TTM) | 4329.99 | 47.31 |
| EV-to-Sales (TTM) | 15.00 | 19.97 |